AI stock analysis · Medical Devices · Last analyzed Aug 18, 2026
Compass Score
3.0/5
Call
Hold
Price
$88.76
AI Target
$94.12 +6.0%
AI Analyst Summary
DexCom is a dominant continuous glucose monitoring (CGM) platform benefiting from rapid adoption across both Type 1 and Type 2 diabetes populations, driving 43.6% YoY EPS growth alongside meaningful operating leverage. With 25 of 25 analysts rating the stock Buy or better and a consistent track record of earnings beats, institutional conviction is exceptionally high. The key risk is revenue growth decelerating to 13.1% YoY, suggesting the top line may be maturing faster than the market expects, potentially pressuring the premium valuation if earnings momentum fades.
Catalysts
Upcoming quarterly earnings report — a 5th consecutive EPS beat would solidify the execution narrative and could drive a re-rating toward the $94 consensus target.
Continued expansion of DexCom's G7 CGM into the Type 2 non-insulin diabetes market, a multi-million patient addressable opportunity that could re-accelerate revenue growth above 13%.
Potential new pharmacy channel partnerships or international reimbursement approvals that expand CGM access and drive incremental unit volume growth in FY2025.
Fundamentals
PeTrailing P/E 35.5x / Forward P/E 28.4x · 3.0/5
Trailing P/E of 35.5x is elevated but not egregious for a high-growth medical device company; forward P/E compresses to 28.4x, suggesting improving earnings power. In-line to slightly above sector median, but growth-justified.
PegPEG 1.69 · 3.0/5
PEG of 1.69 sits in neutral territory — above the 1.0 threshold for deep value but well below 3.0. Reflects a reasonable growth premium given 43.6% YoY earnings growth, though not a bargain on this metric alone.
Analyst RatingStrong Buy consensus (1.3) · 5.0/5
Consensus rating of 1.3 from 25 analysts (25 Buy / 3 Hold / 0 Sell) reflects near-unanimous bullish sentiment. Exceptionally strong analyst conviction with zero sell-side opposition.
43.6% YoY earnings growth is well above the 25% threshold for a top score. Revenue growth of 13.1% is solid for the sector, and the earnings outpacing revenue growth signals meaningful margin expansion — a strong positive signal.
EPS beats in all 4 of the most recent quarters indicate consistent execution. Scored 4 (rather than 5) as only 4 quarters of history are available; full 8-quarter track record would be needed to confirm a perfect score.
ManagementStrong execution; consistent EPS beats with margin expansion · 4.0/5
Flawless 4-for-4 EPS beat rate, combined with earnings growing at 3x the revenue rate, points to disciplined cost management and strong operational execution. Near-unanimous analyst endorsement further corroborates management credibility. Scored 4 pending longer-term beat history.
● See the full picture
Get today's top-scored picks, ranked for you.
Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.
Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →
Not financial advice.
Compass is an analytical tool, not a registered investment adviser or broker-dealer.
Scores and recommendations are generated by AI, may be inaccurate or out of date, and are
not investment, financial, legal, or tax advice. Investing involves risk, including loss of
principal. Do your own research and consult a licensed financial professional.
About Compass.